Drug intelligence / Profile preview

AT-01 (Antharis Therapeutics)

Development stage: Preclinical
Lead developer: Antharis Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AT-01 is a preclinical-stage monoclonal antibody being developed by Antharis Therapeutics for the treatment of various cancers, including lymphoma, multiple myeloma, breast cancer, and kidney neoplasms. The drug is part of a pipeline of next-generation antibodies discovered through DNA-based immunization and unbiased screening strategies. Antharis Therapeutics focuses on immuno-oncology, aiming to enhance the immune system's ability to identify and eliminate malignant cells. AT-01 represents one of the company's lead assets in its effort to address unmet medical needs in both hematological and solid tumors.

Beyond the preview

Go deeper on AT-01 (Antharis Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-01 (Antharis Therapeutics).

Explore the full profile